文献速递心力衰竭与心肌病

心肌纤维化与射血分数保留心力衰竭的时间关系:与基线疾病严重程度及后续结局的关联

Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该观察性队列研究纳入1174例接受心脏磁共振检查且收缩功能保留的患者,发现射血分数保留心力衰竭(HFpEF)与HFpEF高危患者的心肌纤维化(以细胞外容积ECV量化)患病率和程度相似,且均高于无HFpEF者。在HFpEF患者中,ECV与基线BNP水平及后续心衰住院或死亡独立相关。

要点

  • 心肌纤维化可能先于HFpEF临床诊断出现。

核心结论

  • 在BNP升高的HFpEF演化过程中,心肌纤维化在HFpEF患者与HFpEF高危患者中患病率相似。
  • 心肌纤维化与疾病严重程度(BNP)及后续心衰住院或死亡相关。

研究设计与样本

  • 共纳入1174例患者(537例女性,占46%;中位年龄56岁,IQR 44-66岁),其中心脏磁共振排除心脏淀粉样变19例。
  • 250例因BNP升高为HFpEF高危,160例经临床诊断HFpEF,745例无HFpEF。
  • 心肌纤维化通过细胞外容积(ECV)心脏磁共振量化。

主要发现

  • HFpEF高危与HFpEF患者相比无HFpEF者,心肌纤维化患病率和程度相似升高,预后更差。
  • 中位随访1.9年,HFpEF高危或HFpEF患者中61例发生不良事件(19例心衰住院,48例死亡,6例两者兼有)。

临床怎么用

  • ECV可作为HFpEF患者疾病严重程度和预后评估的影像学指标。
  • 对于BNP升高的HFpEF高危患者,应关注心肌纤维化并加强随访。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among myriad changes occurring during the evolution of heart failure with preserved ejection fraction (HFpEF), cardiomyocyte-extracellular matrix interactions from excess collagen may affect microvascular, mechanical, and electrical function. OBJECTIVE: To investigate whether myocardial fibrosis (MF) is similarly prevalent both in those with HFpEF and those at risk for HFpEF, similarly associating with disease severity and outcomes. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study from June 1, 2010, to September 17, 2015, with follow-up until December 14, 2015, at a cardiovascular magnetic resonance (CMR) center serving an integrated health system. Consecutive patients with preserved systolic function referred for CMR were eligible. Cardiovascular magnetic resonance was used to exclude patients with cardiac amyloidosis (n = 19). EXPOSURES: Myocardial fibrosis quantified by extracellular volume (ECV) CMR measures. MAIN OUTCOME AND MEASURES: Baseline BNP; subsequent hospitalization for heart failure or death. RESULTS: Of 1174 patients identified (537 [46%] female; median [interquartile range {IQR}] age, 56 [44-66] years), 250 were "at risk" for HFpEF given elevated brain-type natriuretic peptide (BNP) level; 160 had HFpEF by documented clinical diagnosis, and 745 did not have HFpEF. Patients either at risk for HFpEF or with HFpEF demonstrated similarly higher prevalence/extent of MF and worse prognosis compared with patients with no HFpEF. Among those at risk for HFpEF or with HFpEF, the actual diagnosis of HFpEF was not associated with significant differences in MF (median ECV, 28.2%; IQR, 26.2%-30.7% vs 28.3%; IQR, 25.5%-31.4%; P = .60) or prognosis (log-rank 0.8; P = .38). Over a median of 1.9 years, 61 patients at risk for HFpEF or with HFpEF experienced adverse events (19 hospitalization for heart failure, 48 deaths, 6 with both). In those with HFpEF, ECV was associated with baseline log BNP (disease severity surrogate) in multivariable linear regression models, and was associated with outcomes in multivariable Cox regression models (eg, hazard ratio 1.75 per 5% increase in ECV, 95% CI, 1.25-2.45; P = .001 in stepwise model) whether grouped with patients at risk for HFpEF or not. CONCLUSIONS AND RELEVANCE: Among myriad changes occurring during the apparent evolution of HFpEF where elevated BNP is prevalent, MF was similarly prevalent in those with or at risk for HFpEF. Conceivably, MF might precede clinical HFpEF diagnosis. Regardless, MF was associated with disease severity (ie, BNP) and outcomes. Whether cells and secretomes mediating MF represent therapeutic targets in HFpEF warrants further evaluation.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Schelbert EB, Fridman Y, Wong TC, et al. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. JAMA Cardiol. 2017. PMID: 28768311. doi:10.1001/jamacardio.2017.2511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。